HBP has had a steady week on the TSX, closing at CAD 2.05 on April 29 — up 5.7% on the week and 11.4% over the past month. The interesting tension is not the price move itself, but what's happening in the short book beneath it.
Short sellers have been building a position, though the absolute level remains very small. Estimated short interest climbed roughly 940% over the past month and 73% over the past week, ending the period at just under 1,500 shares shorted — equivalent to a fraction of a percent of the free float at 0.002%. In raw terms, that is a tiny position. The jump in percentage terms reflects a near-zero base in early March, when shorts numbered just 53 shares; by mid-April, that had grown to 1,487 on the ORTEX estimate. Official settlement data from mid-April puts the figure slightly higher at 2,348 shares. Neither reading suggests meaningful short conviction — this is a micro-cap biotech with limited float, and the numbers reflect the scale of the company rather than any aggressive bearish thesis.
The borrow market supports the same read. Cost to borrow is running at approximately 1.8% annually — modest by biotech standards and well below the spike to 6.9% seen in mid-March. That elevated rate has since fully reversed. Availability data is limited here, but the soft borrow cost implies the lending market is not under pressure. The ORTEX short score of 26.9 is effectively flat over the past two weeks, having slipped back from a brief spike to 30.2 in late March. That spike coincided with the March CTB surge and has not been sustained.
The stock's ORTEX short score rank sits at the 92nd percentile relative to its sector, which sounds alarming in isolation but is misleading given the absolute SI level. It reflects the relative change more than any structural crowding. Factor data is sparse: a dividend score of 32 is consistent with a loss-making biotech, and a sector score of 50 is neutral. No analyst coverage, no consensus rating, and no options data are available — standard for a company at this market cap and stage. Enterprise value is broadly around CAD $153 million, though detailed fundamentals are unavailable via this feed for TSX-listed names.
Earnings reaction history is worth noting. The past four reporting events have all produced same-day declines: falls of 7.5%, 12.7%, 17.1%, and 4.6% on the day, with five-day moves even more negative in three of the four cases (the most recent Q3 print saw a five-day loss of 19.5%). The next scheduled event is June 12. Recent insider data is stale — the most current disclosed trades are CEO Thomas Mehrling's two small open-market purchases of HBP stock in July 2025 at around CAD 1.00, totalling roughly 47,000 shares. The stock has roughly doubled since then. Laevoroc Oncology and Laevoroc Chemotherapy collectively hold over 27% of shares, per the last available institutional filing from late 2025, making the float tighter than the headline share count implies.
With June 12 on the calendar, the pattern of post-earnings weakness is what to watch most closely heading into that release.
See the live data behind this article on ORTEX.
Open HBP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
